European Mind & Metabolism Association

Users' LogIn :

support & sponsors welcomed

Donate !!! How ?
  Do go & click here !
You are here: Home arrow Ongoing Research Activity
  • Decrease font size
  • Default font size
  • Increase font size
BDNF, serotonin, & mind ...
EMMA is committed to divulge and to highlight discoveries on new therapeutic tools for diseases of mind and metabolism (e.g., depression, mood disorders, psychoses, mental retardation, etc.).

- BROWSE this section using "Prev" and "Next" buttons at footer of pages.


The brain derived neurotrophic factor and influences of stress in depression.

Kimpton J.

Psychiatr Danub. 2012 Sep;24 Suppl 1:S169-71. Review.


Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases.

Niitsu T, Iyo M, Hashimoto K.

Curr Pharm Des. 2012;18(7):875-83. Review.


The hippocampus, neurotrophic factors and depression: possible implications for the pharmacotherapy of depression.

Masi G, Brovedani P.

CNS Drugs. 2011 Nov 1;25(11):913-31. doi: 10.2165/11595900-000000000-00000. Review.


Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression.

Kunugi H, Hori H, Adachi N, Numakawa T.

Psychiatry Clin Neurosci. 2010 Oct;64(5):447-59. doi: 10.1111/j.1440-1819.2010.02135.x. Review.


Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.

Hashimoto K.

Psychiatry Clin Neurosci. 2010 Aug;64(4):341-57. doi: 10.1111/j.1440-1819.2010.02113.x. Review. Erratum in: Psychiatry Clin Neurosci. 2010 Oct;64(5):590.


Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered.

Hindmarch I, Hashimoto K.

Hum Psychopharmacol. 2010 Apr;25(3):193-200. doi: 10.1002/hup.1106. Review.


Can the sigma-1 receptor agonist fluvoxamine prevent schizophrenia?

Hashimoto K.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):470-4. Review.


Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship.

Hashimoto K.

Cent Nerv Syst Agents Med Chem. 2009 Sep;9(3):197-204. Review.


Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.

Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R, Gardier AM.

Neuropharmacology. 2008 Nov;55(6):1006-14. doi: 10.1016/j.neuropharm.2008.08.001. Epub 2008 Aug 12. Review.


Targeting TrkB neurotrophin receptor to treat depression.

Rantamäki T, Castrén E.

Expert Opin Ther Targets. 2008 Jun;12(6):705-15. doi: 10.1517/14728222.12.6.705 . Review.

Wink New insights into BDNF function in depression and anxiety.

Martinowich K, Manji H, Lu B.

Nat Neurosci. 2007 Sep;10(9):1089-93. Review.


A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors.

Takebayashi M, Hayashi T, Su TP.

Pharmacopsychiatry. 2004 Nov;37 Suppl 3:S208-13. Review.


Critical role of brain-derived neurotrophic factor in mood disorders.

Hashimoto K, Shimizu E, Iyo M.

Brain Res Brain Res Rev. 2004 May;45(2):104-14. Review.


Sealed These papers have also been suggested by EMMA's registered users, who freely act as AUTHORS by providing us LINKS, EVENTS and NEWS. To help us, and to signal new articles on this topic, please access to (or set) your own EMMA's account, using the LOGIN FORM !!!

< Prev

How many online?

Events and Links

Meetings & Congresses

 Index of Congresses ...


the 13th Dresden Symposium on Autoantibodies in September 2017


Debates & Lessons
 User Access:  LOGIN
Beyond science: philosophy, mind and metabolism:
1) Genes, but ...NOT ONLY...

2) Latest hints on innovation: "ALTERNATIVE MEDICINES"

3) The burden of ADHD on modern society (families, health systems).
Societies, Journals (to visit)

Science Societies, Science Journals.

Associations to help people with a psychiatric disease (and their families).


Which of these lotteries would you bet a stake on?